Ikonisys S.A.

Paris Stock Exchange ALIKO.PA

Ikonisys S.A. Debt to Equity Ratio for the year ending December 31, 2023: 0.22

Ikonisys S.A. Debt to Equity Ratio is 0.22 for the year ending December 31, 2023, a 52.40% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Ikonisys S.A. Debt to Equity Ratio for the year ending December 31, 2022 was 0.14, a 128.50% change year over year.
  • Ikonisys S.A. Debt to Equity Ratio for the year ending December 31, 2021 was 0.06, a 78.28% change year over year.
  • Ikonisys S.A. Debt to Equity Ratio for the year ending December 31, 2020 was 0.03, a -28.55% change year over year.
  • Ikonisys S.A. Debt to Equity Ratio for the year ending December 31, 2019 was 0.05.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
SV Wall Street
Paris Stock Exchange: ALIKO.PA

Ikonisys S.A.

CEO Mr. Mario P. Crovetto
IPO Date July 19, 2021
Location France
Headquarters 62 Rue De Caumartin
Employees 10
Sector Health Care
Industries
Description

Ikonisys S.A., a cell based diagnostics company, engages in the design, manufacturing, marketing, and sale of medical diagnostic products for various cancers in the United States and Europe. It offers Ikoniscope Robotic Microscope that provides automated slide handling, slide scanning, and real-time image capture and analysis, and eliminates various factors that cause human error in testing; oncoFISH bladder that allows scanning and analysis of cells recovered from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; and oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of rearrangements of the gene encoding anaplastic lymphoma kinase (ALK). The company also provides oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer CS, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; Ikonisoft explorer tissue, a FISH scanning application for analysis of various tissue section hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. Ikonisys S.A. is based in Paris, France.

Similar companies

AFME.PA

Affluent Medical SA

USD 1.43

2.69%

ALENO.PA

Enogia SAS

USD 2.37

9.83%

ALNFL.PA

NFL Biosciences SA

USD 1.71

-4.34%

StockViz Staff

January 31, 2025

Any question? Send us an email